Table 2. Efficacy in the BMS-986156 Plus Nivolumab Combination Cohort.
| Outcome | 30 mg of BMS-986156 + 240 mg of Nivolumab (n = 3) | 100 mg of BMS-986156 + 240 mg of Nivolumab (n = 9) | 240 mg of BMS-986156 + 240 mg of Nivolumab (n = 200) | 800 mg of BMS-986156 + 240 mg of Nivolumab (n = 11) | 480 mg of BMS-986156 + 480 mg of Nivolumab (n = 29) |
|---|---|---|---|---|---|
| BOR, No. (%) | |||||
| CR | 0 | 0 | 2 (1.0) | 0 | 0 |
| PR | 0 | 1 (11.1)a | 16 (8.0)b,c | 1 (9.1) | 1 (3.4) |
| SD | 1 (33.3) | 2 (22.2) | 65 (32.5) | 5 (45.5) | 11 (37.9) |
| PD | 2 (66.7) | 4 (44.4) | 95 (47.5) | 4 (36.4) | 12 (41.4) |
| NE | 0 | 2 (22.2) | 14 (7.0) | 0 | 2 (6.9) |
| Confirmed ORR, No. (%) [95% CI] | 0 [0.0-70.8] | 1 (11.1) [0.3-48.2] | 18 (9.0) [5.4-13.9] | 1 (9.1) [0.2-41.3] | 1 (3.4) [0.1-17.8] |
| Confirmed DCR, No. (%) [95% CI] | 1 (33.3) [0.8-90.6] | 3 (33.3) [7.5-70.1] | 83 (41.5) [34.6-48.7] | 6 (54.5) [23.4-83.3] | 12 (41.4) [23.5-61.1] |
Abbreviations: BOR, best overall response; CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.
a
This patient had prior treatment with pembrolizumab, with a BOR of PD, ending 111 weeks before initiation of study treatment.
b
One of these patients had prior treatment with nivolumab, with a BOR of PD, ending 4 weeks before initiation of study treatment.
c
One of these patients had prior treatment with pembrolizumab, with a BOR of PR, ending 83 weeks before initiation of study treatment.